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Growing evidence over the last few years suggests a central role of type I IFN pathway in the pathogenesis of systemic autoimmune
disorders. Data from clinical and genetic studies in patients with systemic lupus erythematosus (SLE) and lupus-prone mouse
models, indicates that the type I interferon system may play a pivotal role in the pathogenesis of several lupus and associated
clinical features, such as nephritis, neuropsychiatric and cutaneous lupus, premature atherosclerosis as well as lupus-speciﬁc
autoantibodiesparticularlyagainstribonucleoproteins.Inthecurrentpaper,ouraimistosummarizethelatestﬁndingssupporting
the association of type I IFN pathway with speciﬁc clinical manifestations in the setting of SLE providing insights on the potential
u s eo ft y p eII F Na sat h e r a p e u t i ct a r g e t .
1.Introduction
Systemic lupus erythematosus (SLE) is the prototype of
systemicautoimmunedisorders,aﬀectingvirtuallyanyorgan
system of mainly young women of child-bearing age, at an
incidence ranging from 2 to 5 cases per 100,000 persons. It
is characterized by remarkable heterogeneity in regard to the
spectrum and severity of clinical and laboratory manifesta-
tions, with disease activity ﬂuctuating considerably during
the course of the disease. While genetic susceptibility along
with environmental interactions contributes signiﬁcantly to
the immune dysregulation that characterizes SLE, the exact
etiopathogenesis remains elusive [1].
In the late 1970s, increased serum levels of interferon
(IFN) were shown for the ﬁrst time to be signiﬁcantly
associated with SLE and to correlate with disease activity
[2]. Later reports showing that chronic treatment with
recombinant IFNα in patients aﬀected with malignancies
induces autoimmune manifestations [3]c o u p l e db ys u b s e -
quent studies documenting heightened serum levels of type I
IFN and type I IFN-inducible genes [4] in patients with SLE
reinforced the hypothesis that type I IFN has a major role
in the pathogenesis of SLE. Although the exact triggers of
type I IFN activation in SLE are unknown, exogenous viral
agents or endogenous nucleic acids seem to be potential can-
didates through sensing of pattern recognition membrane
and cytosolic receptors of specialized IFNα-producing cells
such as plasmacytoid dendritic cells (pDCs), while genetic
contributors in generation of type I IFN in SLE have been
also implicated [5]. Of note, recent data have shown that
mature neutrophils from lupus patients undergo apopto-
sis upon exposure to SLE-derived anti-ribonucleoprotein
antibodies releasing neutrophil extracellular traps (NETs)
that contain DNA and neutrophil-derived proteins. The SLE
NETs eﬃciently activate the pDCs to produce type I IFNs,
thus, acting as an endogenous stimulus for the type I IFN
pathway [6, 7].
In the current paper, our aim is to summarize the latest
ﬁndings previously shown to support the association of type
I IFN pathway with speciﬁc clinical manifestations of SLE
particularly those characterized by renal, skin, neurological
involvement, as well as concomitant atherosclerosis provid-
ing insights on the potential use of type I IFN as a biomarker
and/or therapeutic target in these patients. To the best of our2 Journal of Biomedicine and Biotechnology
knowledge, no data to date support the association of type I
IFN activation with other lupus-related manifestations such
as serositis or arthritis.
2. TypeI IFNand LupusNephritis
Lupus nephritis and the progression to end-stage renal
disease represent one of the major causes of morbidity
and mortality in SLE patients. Almost half of the patients
with SLE present with clinical lupus nephritis, and up to
90% of patients have some degree of histological renal
damage. Diﬀerent interacting pathogenetic mechanisms
such as immune complex deposition, renal inﬁltration by
T cells, macrophages, and dendritic cells, activation of toll-
like receptors (TLRs), and a variety of cytokines as well as
end-organ responses to immune injury contribute to the
pathogenesis of lupus nephritis [15].
Despite data deriving both from murine lupus models
andpatientswithSLEsupportingapathogeneticrolefortype
II IFN (IFNγ), there is ever increasing evidence indicating
type I IFNs as one of the major players in the pathogenesis
of lupus nephritis. In 1979, Hooks et al. noticed for the ﬁrst
time a signiﬁcant association of type I IFN serum levels with
active lupus [2]. Two years later, Rich reported that typical
lupus inclusions (detected in the glomerular endothelium
in almost all lupus patients and in the peripheral blood
lymphocytes of more than two-thirds) were induced by
type I IFN in the Raji cells, a human B-lymphoblastoid cell
line of Burkitts lymphoma origin [16]. Since then, several
studies in patients with SLE have demonstrated a signiﬁcant
association between both type I IFN serum levels and IFN-
induced gene expression in peripheral blood mononuclear
cells (PBMCs)—the so-called interferon signature—[2, 8–
14] with disease activity and other disease-related features
including lupus nephritis (Table 1). It should be noted
that the largest so far study performed by Weckerle et al.,
which included 1089 patients from 3 diﬀerent ancestral
backgrounds, showed a strong association between certain
autoantibodies and high IFNα activity but failed to detect
signiﬁcant association with clinical features of the disease.
However, disease activity was not assessed in this study.
In addition to the aforementioned studies associating type
I IFN and clinical and serological features of SLE, cDNA
microarray analysis of gene expression in glomeruli, isolated
by laser-capture microscopy from kidney biopsies of lupus
patients with focal/diﬀuse proliferative glomerulonephritis,
revealed increased expression of type I IFN-inducible genes,
thus, implying a possible pathogenetic role for type I IFN
in these patients [17]. Glomerular expression of TLR-9,
an endosomal sensor of CpG DNA leading to type I IFN
production,wasreportedinpatientswithlupusnephritisbut
not in healthy controls and was associated with anti-dsDNA
and higher activity index of lupus nephritis [18].
Moreover, recent genetic association studies have identi-
ﬁed many lupus-associated genetic variants in genes encod-
ing transcription factors and various molecular compo-
nents involved in the type I IFN pathway [19–37]. Studies
investigating a possible association between genotype and
phenotype in lupus patients have brought to light conﬂicting
resultsregardingtheassociationwithlupusnephritis.Acase-
control study by Taylor et al. in a large cohort of North
American patients of European descent showed a signiﬁcant
association between the single nucleotide polymorphism
(SNP) rs7574865 of the STAT4 gene and lupus nephritis,
anti-dsDNA and early disease onset [38]. Accordingly, SNPs
of the STAT4 gene was associated with lupus nephritis and
anti-dsDNA in a cohort of 695 Swedish patients [24]. Similar
results, although not statistically signiﬁcant probably due
to small sample size, were reported in a Japanese study for
the SNP rs7574865 of STAT4 gene [39]. In contrast, the
same SNP of STAT4 was not associated with any speciﬁc
clinical manifestation of lupus in a Northern Han Chinese
case-control study. This may be attributed to diﬀerences in
immune pathways inﬂuenced by this polymorphism among
diﬀerent populations. An alternative explanation could
derive from the fact that rs7574865 with nearby SNPs can
form diﬀerent haplotype blocks each one conferring a dis-
tinct risk for SLE and for speciﬁc SLE manifestations. There-
fore, the diverse eﬀect of this risk SNP in SLE subphenotypes
couldbeexplainedbythepresenceofdistinctriskhaplotypes
among diﬀerent ethnic groups. In the same study, 2 more
SNPs, rs4963128 and rs2246614 of the interferon-regulatory
factor 7 (IRF7) gene, were tested for association with SLE. In
contrast to what was observed in a European women cohort
[20], no association with increased susceptibility for SLE in
northern Han Chinese was reported. However, these 2 SNPs
were associated with diﬀerent subphenotypes of SLE. In
particular, the rs4963128 was associated with the production
of anti-SSA/B antibodies and lupus nephritis. The authors
suggest that particular variants of the IRF7/KIAA1542 region
may induce the generation of certain autoantibodies [32].
A recent small study of 190 Chinese patients with lupus
nephritis reported a signiﬁcant association of the rs2004640
polymorphism of the interferon-regulatory factor 5 (IRF5)
gene with lupus nephritis but showed no association with
any speciﬁc histological or clinical manifestation of lupus
kidney disease [40]. However, a Swedish study, consisting
of 272 SLE patients, investigating several SNPs related to
IRF5 (including the rs2004640 polymorphism tested in the
a f o r e m e n t i o n e dC h i n e s es t u d y ) ,a sw e l la sr i s kS N P so f
STAT4 and TNF receptor-associated factor-1 complement
component-5 (TRAF1-C5) demonstrated no association
with lupus nephritis [41]. However, it should be noted
that this was a study primarily investigating a possible
overlap in genetic susceptibility between IgA nephropathy
and lupus nephritis. Moreover, the small sample size of
this study does not oﬀer suﬃciently powered results to
contradict the positive association between risk alleles in
STAT4 gene and lupus nephritis demonstrated in other
studies. Taken together, the data provided by genetic studies
further support the association of the type I IFN pathway
with SLE susceptibility and possibly with lupus nephritis at
least in some ethnic groups (Table 2).
This association between type I IFN and lupus nephritis
in humans, which per se does not deﬁne a direct cause-
eﬀect relationship, has been put to test in many experimental
murinelupusmodelsinordertoclarifythepathogeneticroleJournal of Biomedicine and Biotechnology 3
Table 1:StudiesinpatientswithSLEshowingstatisticalsigniﬁcantassociations(P<0.05)betweenperipheraltypeIIFNactivityandclinical
and serological features.
Author No. of
patients
Type I IFN
levels
Type I
IFN-inducible
genes
Clinical associations Serological
associations
Hooks et al. [2] 28 High NM Disease activity Anti-dsDNA
Low C3
Kanayama et al. [8] 25 High NM Fever NM
Bengtsson et al. [9] 30 High NM
Disease activity
Fever
Skin
Anti-dsDNA
Low C1q
Low C3
Leucopenia
Baechler et al. [10] 48 NM High Renal and/or NPSLE
Hematologic NM
Dall’era et al. [11] 65 High NM Disease activity
Skin
Anti-dsDNA
Low C3
Kirou et al. [12] 77 NM High Renal
Anti-dsDNA
Anti-Ro
Anti-U1 RNP
Anti-Sm
Low C3
Low C4
Feng et al. [13] 48 NM High
Renal
NPSLE (weak
association)
Anti-dsDNA
Anti-Sm
Anti-Ro/La
Low C3
Weckerle et al. [14] 1089 High NM NS Anti-dsDNA
Anti-Ro
NM: not measured, NS: not statistically signiﬁcant. All abbreviations are explained in the text.
of type I IFN in lupus renal disease. Studies in autoimmune
prone mice that were treatedwith polyinosinic:polycytidylic
acid (poly I:C), a synthetic double-stranded RNA ligand for
TLR-3 that strongly induces type I IFN response, showed
higher titers of anti-dsDNA antibodies, increased immune
complex deposition, accumulation of activated lymphocytes
and macrophages, and increased metalloproteinase activity
that led to accelerated lupus nephritis and death [43–45].
Similar results supporting the pathogenetic eﬀect of type I
IFNinlupusglomerulonephritiswereobtainedfrommurine
models injected with adenovirus expressing IFNα that leads
to sustained release of that cytokine [45–49]. Moreover,
recent studies in healthy (not lupus-prone) mice treated with
2,6,10,14-tetramethylpentadecane (pristane), an inducer of
type I IFN through TLR-7 signaling, resulted in lupus-
like nephritis, possibly through recruitment of inﬂammatory
cells by type I IFN-inducible chemokines. Interestingly,
diﬀerent strains of mice under the eﬀect of pristane develop
histological lesions of diverse severity probably due to yet
unknown genetic factors [50]. These data demonstrate that
increased levels of type I IFN are able to induce lupus
nephritis both in lupus-prone and healthy mice.
Additional evidence supporting the pivotal role of type
I IFN in lupus glomerulonephritis derives from studies in
New Zealand Black (NZB), New Zealand, mixed 2328 as
well as pristane-treated mice deﬁcient of the receptor of
type I IFN (IFNAR−/−). The defective signaling through
IFNAR in IFNAR−/− mice conferred protection from kidney
disease and was associated with a decrease in the titers of
lupus-speciﬁc autoantibodies and disease severity. In these
models, a decrease in the proliferation and activation of
dendritic cells as well as B and T cells was documented [51–
53]. However, one study conducted in congenic MRL/lpr
mice, a lupus-prone model that develops severe crescentic
glomerulonephritis, reported that IFNAR deﬁciency caused
a signiﬁcant deterioration of renal disease. In contrast,
deﬁciency of the type II IFN (IFNγ) receptor had beneﬁcial
eﬀects on kidney disease, thus, suggesting a protective role
for type I IFN pathway at least in this mouse model [54].
The role of TLRs and especially of TLR-7, responsive
to ssRNA, and TLR-9, responsive to hypomethylated CpG-
rich DNA, in type I IFN production in lupus is well
established. Studies in mice that overexpress TLR-7 (Y-
linked autoimmune accelerating locus mice—Yaa mice) or
that were treated with pristane demonstrate the importance
of type I IFN and TLR-7 signaling in accelerating and
aggravating kidney injury [55–57]. Interestingly a study by
Thibault et al. using the pristane-induced mouse model
of SLE showed that upregulation of TLR-7 receptors in B
cells and eﬀective activation through TLR-7 and TLR-9 of
B cells to produce lupus-speciﬁc autoantibodies require an
intact type I IFN signaling pathway, thus, suggesting that
type I IFN is upstream of TLR signaling in the activation
of autoreactive B cells in SLE [58]. Moreover, activation4 Journal of Biomedicine and Biotechnology
Table 2:GeneticstudiesinvestigatingtheassociationbetweenseveralSNPsandbothlupusnephritisandspeciﬁcauto-antibodiesindiﬀerent
ethnic populations.
Author No. of SLE
patients
No. of healthy
controls Ethnicorigin Gene/SNP studied
Associations
Nephritis Autoantibodies
Taylor et al. [38] 1396 2560
North
Americans
(European
descent)
STAT4/
rs7574865 P<10
−11∗ Anti-dsDNA/
P<10
−19
Kawasaki et al. [39] 308 306 Japanese STAT4/
rs7574865 P = 1.0 ×10
−5∗∗ Anti-dsDNA/
P = 4.9 ×10
−5∗∗
Qin et al. [40] 190 182 Chinese IRF5/
rs2004640T P = 0.002
∗∗∗ NS
-STAT4/
rs10181656
−NS −NM
Vuong et al. [41] 272 307 Swedish
-IRF5/
rs729302
rs4728142
rs2004640
rs3807306
rs10954213
rs11770589
rs2280714
−NS −NM
-TR AF 1 -C5 /
rs3761847
−NS −NM
-TGFB1/
rs6957
rs2241715
rs1982073
rs1800469
−NS −NM
Li et al. [32] 748 750 Chinese
(Northern Han)
-STAT4 /
rs7574865
−NS −NS
-IRF7/
KIAA1542
−P = 3.78 ×10
−8 -Anti-SSB/
P = 9.63x10 −6
rs2246614†− NS −NS
Luan et al. [42] 675 678 Chinese STAT4/
rs7582694
−NS −NS
Sigurdsson et al. [24] 695 — Swedish STAT4/
rs7582694 0.04 Anti-dsDNA/
P = 5.3 ×10
−7
∗Severe nephritis (ESRD or severe progressing renal disease in renal biopsy), P<10−4.∗∗Statistical signiﬁcance found only in the case-control arm of the
study, whereas, in the case-only arm of the study, results both for nephritis and anti-dsDNA reached no statistical signiﬁcance.
∗∗∗While a statistically signiﬁcant association with lupus nephritis was detected, no association was found with any speciﬁc clinical ﬁnding or histological
type of nephritis.
†These 2 SNPs of the IRF7/KIAA1542 gene were not associated with SLE but only with speciﬁc SLE subphenotypes such as nephritis and anti-SSB.
NS: not statistically signiﬁcant association. NM: not measured.
The rest of the abbreviations used are explained in the text.
of TLR-9 signaling pathway through CpG-rich DNA was
shown to induce severe lupus nephritis in lupus-prone mice
[59]. Additional conﬁrmation was obtained from a study
that tested a dual inhibitor of TLR-7 and TLR-9 (known to
inhibit IFNα production by pDCs) in lupus-prone mice. A
signiﬁcant improvement of proteinuria, glomerulonephritis,
and survival as well as a reduction of serum levels of nucleic
acid-speciﬁc autoantibodies was observed [60].
Further evidence emphasizing the central role of type
I IFN in lupus nephritis came from studies investigating
the cellular source of type I IFN in lupus nephritis. pDCs
are well known to be the main type I IFN-producing cells
and potentially responsible for the systemic increase of type
I IFN levels. Tucci et al. showed that peripheral pDCs
were decreased in SLE patients and that this was associated
with lupus nephritis. Moreover, this study demonstrated the
presence of pDCs in the glomeruli of patients with severe
lupus nephritis [61]. Interestingly, other studies suggest that
immaturemonocytesrecruitedinthekidneys[62,63]aswell
as resident renal cells [64] represent the main source of type
I IFN in the kidney, thus, promoting end-organ disease in
murine lupus nephritis models.
Finally a recent study by Ichii et al. showed that over-
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correlated with the progression of lupus nephritis in the
B6.MRLc1 (82–100) mice. Iﬁ202 is an IFN-stimulated gene
localized on the murine chromosome 1, and its overex-
pression in the kidneys and in the immune organs was
conﬁrmed in many lupus-prone mouse models such as
BXSB, NZB/WF1 and MRL/lpr. This further supports the
role of this IFN-stimulated gene in the pathogenesis of lupus
nephritis and lupus susceptibility in general [65].
Taken together, these data highlight the importance of
the IFN system in lupus nephritis creating exciting new
prospectivesbothatdiagnosticandclinicallevels.Interferon-
induced chemokines, like macrophage chemoattractant pro-
tein 1 (MCP-1) and others, seem to be highly sensitive
biomarkers in the assessment of current disease activity
and in the early detection of lupus nephritis ﬂare [66,
67]. Moreover, inhibition of MCP-1 in a murine model of
lupus nephritis showed signiﬁcant amelioration of disease
symptoms suggesting a new therapeutic approach to lupus
kidney disease [68]. Zagury et al. successfully used an IFNα
immunogen (termed IFNα kinoid) in mice with nephritis
thattransiently induces anti-IFNα antibodies resultinginnet
improvement of lupus nephritis [69]. On the other hand,
MRL-Faslpr mice treated with IFNβ showed a signiﬁcant
amelioration of lupus nephritis in these mice suggesting that
IFNβ exerts a local (rather than systemic) anti-inﬂammatory
eﬀect [70]. Additionally, phase I human clinical trials using
anti-IFNα monoclonal antibody in patients with mild to
moderate SLE showed promising results including sup-
pression of type I IFN-inducible genes overexpression in
whole blood and skin lesions, profound eﬀects on signaling
pathways such as BAFF, TNFα,I L - 1 β and consistent trends
toward improvement in disease activity, reduced number
of ﬂares, and decreased requirement for new or increased
immunosuppressive treatments. Preliminary data regarding
the safety proﬁle especially viral infections and major
adverse events support further clinical development [71–73].
However, more data regarding the eﬃcacy and safety of this
treatment are awaited.
3.TypeI IFNandCutaneousLupus
Erythematosus(CLE)
Cutaneous lupus erythematosus (CLE) is one of the most
common autoimmune-associated skin diseases worldwide.
In most cases, the disease is localized and limited to the
skin area, without multisystemic involvement characteristic
of SLE. While approximately 10%–40% of CLE—depending
on the clinical subset of CLE—may transit to systemic
disease, skin lesions in the setting of SLE can occur in
up to 70% of patients during the disease course [74, 75].
While the pathogenesis of the CLE remains still unclear,
a number of contributors—among them type I IFNs—
have been proposed. In line with this hypothesis, lupus-
like skin lesions have been previously reported at the site
of injection of recombinant IFNα and IFNβ in patients
with malignancy and multiple sclerosis respectively, while
patients with generalized CLE features often experience ﬂu-
like symptoms [76, 77]. In patients with lupus, upregulation
of the IFN-inducible antiviral protein Myxovirus A (MxA)
in CLE has been ﬁrst reported by Fah et al. [78], a ﬁnding
which has been later conﬁrmed in discoid (DLE), subacute
cutaneous (SCLE), as well as other lupus-associated rashes
[74, 79, 80]. Of interest, MxA expression was mainly seen in
theepidermisandtheupperdermisinDLEandSCLE,while,
in rarer cases of lupus tumidus and lupus profundus, MxA
was mainly detected in perivascular and subcutaneous areas,
respectively, reﬂecting the distribution of the inﬂammatory
inﬁltrate in diﬀerent subsets of CLE [74].
Intracellular IFNα itself has been detected at mRNA and
proteinlevelinalllesionalandmorethanhalfofnotinvolved
skin specimens from 11 lupus patients compared to only
one out of 11 healthy controls [81]. The overexpression
of IFN-related genes in nonpathological skin might be the
result of genetically determined IFN pathway activation in
these patients. Despite the enhanced expression of the IFNα-
inducible IRF7 gene in CLE lesions reported by Meller et al.
IFNα mRNA expression has been reported not signiﬁcantly
diﬀerent in CLE skin compared to normal skin [82].
Subsequent studies detected the accumulation of pDCs—the
classicalIFNαproducingcells—inlesionalskinfrompatients
withDLE,SLE,andlupustumidus,providinganexplanation
for the previously reported reduced pDC numbers in lupus
patients [79, 82–85]. Two pDC subsets have been identiﬁed
according to their distribution pattern in CLE skin biopsies:
a dermal pDCs subset (D-pDC) surrounding dermal vessels
associated with Th1 responses and a second subset at the
dermoepidermal junction zone (J-pDC) in association with
cytotoxic T lymphocytes and subsequent local epithelial
damage [84]. In the same study, a positive association was
found between the pDC numbers and the density of the
inﬁltrate,suggestingthatIFNαproductioncouldregulatethe
degree of inﬂammation in the aﬀected skin areas. Of note, a
higher density inﬁltrate has been shown in DLE compared to
SLE patients [84].
As a result of the locally produced IFNα, recruitment
of lymphocytes in the CLE lesion occurs through the
production of IFNα-a n dγ-inducible chemokines CXCL9,
CXCL10, CXCL1, which share a common lymphocytic
CXCR3 receptor. Compared to IFNγ,I F N α has been shown
to induce earlier production of these chemokines by ker-
atinocytes, dermal endothelial cells, and dermal ﬁbroblasts,
ensuring a ﬁrst wave of CXCR3+ lymphocytic migration—
at the site of the CLE lesion [82]. These ﬁndings provide
an explanation for the peripherally decreased number of
CXCR3+—lymphocytes in these patients [86].
Serum type I IFN activity or expression of IFN-inducible
genes in PMBCs from lupus patients was found to be
associated with the presence of lupus-associated rashes in
some but not all studies so far performed. Of interest, a
positive trend between a history of photosensitivity and type
I IFN-induced gene expression has been reported by Kirou et
al. [9–13].
While the initial trigger for pDC activation in CLE
remains elusive, observations of cutaneous lupus ﬂares after
sun exposure coupled with experimental evidence suggests
UV irradiation as a central player in initiation of the lupus-
associated skin injury. UV irradiation has been shown to6 Journal of Biomedicine and Biotechnology
exaggerate the already enhanced apoptosis of keratinocytes
in CLE leading to generation of RNA and DNA fragments
with subsequent secondary necrosis, production of a variety
of IFNα-induced chemokines which in turn lead to lympho-
cytic recruitment and subsequent local inﬂammatory tissue
injury [82, 87]. In accord with the proposed mechanism,
inhibitors of TLR7 and TLR9 signaling in a lupus-prone
murine model of interface dermatitis attenuated the skin
lesions [88].
Moreover, a recently identiﬁed IFNα-a n dγ-induced
protein—the GTPase human guanylate binding protein-
1 (GBP-1)—is expressed by keratinocytes and endothelial
cells in primary and ultraviolet- (UV-) induced skin lesions
from patients with various subtypes of CLE compared to
nonlesional skin [89]. It has also been recently demon-
strated that the IFNα-inducible IFI16 protein—normally
localized in the nucleus—translocates in the cytoplasm of
aﬀected skin cells from lupus patients and in UV irradiated
keratinocytes—leading to generation of antibodies against
the IFNα-inducible IFI16 recently detected in sera of lupus
patients [90].
4.TypeI IFNandNeuropsychiatricSystemic
LupusErythematosus(NPSLE)
Neuropsychiatric systemic lupus erythematosus (NPSLE)—
among the most severe manifestations of SLE—includes a
variety of manifestations involving central, peripheral, and
autonomic nervous system as well as psychiatric disorders
after other underlying causes have been carefully excluded.
The prevalence of neuropsychiatric manifestations in the
setting of SLE varies at a range approximately between 15%
and 75%, depending of the ascertainment method used [91].
Several mechanisms have been so far implicated
in the etiopathogenesis of NPSLE, including antibody-
mediated vascular and parenchymal brain injury, con-
comitant atherosclerotic disease, or the eﬀect of various
inﬂammatory cytokines, including among others inter-
leukin 1β (IL1β), tumor necrosis factor α (TNFα), IFNγ,
and IFNα. These cytokines have been shown to induce
peripheral depletion of tryptophan—previously implicated
in the pathogenesis of depression—through stimulation of
the enzyme indoleamine 2,3-dioxygenase [92]. IFNα has
been also shown to induce the IFNγ-inducible protein 10
(IP-10) and interleukin-6 (IL6) previously implicated in
pathogenesis of CNS abnormalities [93].
Induction of SLE-like syndromes and neuropsychiatric
manifestations have been reported after therapeutic use
of IFNα approximately in one-third of patients mainly
with hepatitis C or certain malignancies giving potential
insights of type I IFN implication in lupus-related clinical
syndromes [94–96]. While depression seems to be among
the most common IFNα-related neuropsychiatric side eﬀects
and a main contraindication for IFNα administration,
psychotic features, confusion, bipolar disorders, and seizures
can also occur [92]. IFNα production by astrocytes in
transgenic mouse models revealed structural and functional
abnormalities ranging from seizures and severe behavioral
disorders with high mortality to more subtle learning
disabilities depending on high or low intrathecal levels of
IFNα,r e s p e c t i v e l y[ 97]. Notably, calcium and phosphorus
depositioninthebraininthisexperimentalmodelresembled
the mineral deposition observed in basal ganglia from
patientswiththeAicardi-Goutieressyndrome,anearly-onset
encephalopathy with elevated CSF IFNα levels. The Aicardi-
Goutieres syndrome is an autosomal recessive disease related
to mutations in 5 genes, including among others the 3-repair
DNA exonuclease 1 (TREX1), recently associated with lupus
[98].
T h eﬁ r s te v i d e n c eo ft y p eII F Ni m p l i c a t i o ni nN P S L E
pathogenesis comes from an early small study in the 1980s,
in which elevated CSF levels of IFNα w e r ed e t e c t e di n2o u t
of 15 patients with SLE and CNS involvement but not in
20 non-NPSLE individuals. Both of these patients suﬀered
from psychosis and were characterized by the presence of
CSF oligoclonal IgG [99].
In accord with the above ﬁndings, elevated IFNα levels
have been subsequently detected in CSFs of ﬁve out of
6 lupus patients with psychosis but with no other NP
manifestations. In the brain autopsy of one of the study
participantswhodiedfromgeneralizedseizures,thepresence
of IFNα in neurons and microglia has been demonstrated by
immunochemistry [100]. However, elevated IFNα levels—
measuredbyimmunoassay—weredetectedinapproximately
one-ﬁfth of CSFs of both 28 NPSLE and 14 non-NPSLE
patients, suggesting a limited diagnostic role for IFNα in
clinical grounds [101]. While no signiﬁcant diﬀerences have
been observed in serum levels of interferogenic activity—
measured by bioassay—between SLE patients with and
without neuropsychiatric involvement, CSF interferogenic
activity has been found to be elevated in NPSLE patients
compared to controls with other autoimmune disorders
and CNS features. Of note, remarkably lower levels of
interferogenic activity have been observed in sera compared
to CSFs of NPSLE patients. This was partially attributed
to an inhibitory eﬀect of serum IgG, providing a potential
explanation for the success of intravenous immunoglobulin
(IVIG) treatment in some cases of NPSLE [102] and other
neurological diseases [103, 104]. In a recent study, involving
59 NPSLE patients, it was observed an association between
acute ﬂares of NP manifestations and elevated IFNα activity
in the CSF [105].
TheCSFinterferogenicactivityseemstoresultfrompDC
stimulation by CSF-containing immunocomplexes formed
by autoantibodies and antigens released by neurocytotoxic
Abs or other injured brain cells [93] .W h i l ep D C sh a v en o t
been studied in the NPSLE patients brain cells, elevated
number of pDC cells has been isolated from the CSF of other
neuroinﬂammatory diseases [106].
In regard to peripherally detected type I IFN activity in
NSPLE, in a cohort of 48 SLE patients reported by Feng
et al., signiﬁcantly higher IFN-inducible gene expression
in peripheral mononuclear cells has been demonstrated in
9 patients, who ever suﬀered from psychosis or seizures,
compared to those without those manifestations [13]. Such
an association was not, however, observed in a larger cohort
of 77 SLE patients by Kirou et al. (Table 1). Moreover, inJournal of Biomedicine and Biotechnology 7
Genetic
susceptibility
(STAT4 risk allele?)
LDGs
NETs
pDCs
Platelet
Subintimal Mφ
↑IFNα
↑↑↑Expression of SR
↑Platelet
activation
↑Internalization of
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a recent cross-sectional study including 58 SLE patients,
no correlation between depression scores and type I IFN-
induced gene expression in PBMC has been detected [107].
Taken together, these data imply a potential involvement
of type I IFN system in pathogenesis of lupus-related CNS
features. Prospective studies with larger number of patients
and careful collection of clinical, serological, and imaging
data are required to further understand its contribution in
pathogenesis of NSPLE.
5. Type I IFNand Atherosclerosis in
SLE Patients
Extensive epidemiological studies in SLE patients demon-
strate a bimodal distribution in mortality rates with the
earlier peak attributed to infections and complications from
kidney disease and/or neuropsychiatric lupus and a later
peak mainly linked to atherosclerotic cardiovascular (CV)
events [1]. A population-based case-control analysis, using
general practice database data, found a relative CV disease
risk of 2 for women with SLE [108, 109]. Strikingly, a ﬁfty-
fold increased risk of myocardial infarction was reported
amongpremenopausalwomenwithSLE[110].Whileseveral
traditional risk factors for atherosclerosis are more prevalent
amongSLEpatients,theycannotfullyexplaintheirincreased
CV burden [111]. Additionally, the eﬀe c to nC Vr i s ko f
SLE is more pronounced comparing to the impact of
other inﬂammatory diseases like rheumatoid arthritis [108].
These observations support the hypothesis that accelerated
atherosclerosis and premature CV disease are signiﬁcantly
enhanced by factors inherent to the pathogenesis of SLE.
Among these, increasing evidence designates type I IFN as
a major player in promoting both the pathogenesis of SLE
and atherosclerosis (Figure 1).
It is widely believed that atherosclerosis results from
chronic endothelial injury paired with a defective vascular
repair mechanism leading to invasion of inﬂammatory cells,
lipid deposition, vascular smooth muscle proliferation, and
neointima formation. Several studies suggest that circulating
myeloid-derived endothelial progenitor cells (EPCs) and
myelomonocytic circulating angiogenic cells (CACs) are the
key players in the vascular repair mechanism [112, 113].
Interestingly, reduced number and/or functional abnor-
malities of EPCs/CACs have been documented in patients
with SLE [114–118]. Moreover, heightened type I IFN8 Journal of Biomedicine and Biotechnology
levels were associated with EPCs depletion and endothelial
dysfunctioninSLEpatientspossiblythroughIFNα-mediated
apoptosis of EPCs/CACs and induction of diﬀerentiation
of myeloid cells to nonangiogenic phenotypes. Neutralizing
the type I IFN pathway redressed the abnormal EPC/CAC
phenotype [119, 120]. In accord with the human studies, in
alupus-pronemurinemodel,elevatedlevelsoftypeIIFNled
to reduced number and EPCs dysfunction [121]. Moreover,
the presence of IFNα inhibited EPCs from nonlupus-prone
mice to diﬀerentiate into mature endothelial cells. Thacker
et al. showed that IFNα represses the transcription of the
proangiogenic factors IL1 α and β and vascular endothelial
growth factor A (VEGF) and upregulates the antiangiogenic
IL1 receptor antagonist. In vivo conﬁrmation of this antian-
giogenic pathway of IFNα interfering with IL1 pathways
was established by examining renal biopsies of patients with
lupus nephritis [122].
Furthermore, studies investigating the cellular source of
type I IFN add supporting evidence to the eﬀects of type
I IFN in vascular injury. pDCs have been implicated in
the pathogenesis of atherosclerosis and in particular in the
destabilization of the atherosclerotic plaque which leads to
acute vascular events through upregulation of TNF-related
apoptosis-inducing ligand (TRAIL) on CD4+ T cells which
enhance them to kill plaque-resident cells, thus, rendering
the plaque vulnerable [123]. However, depletion of pDCs
does not reverse the abnormal EPC/CAC phenotype in vitro.
A recently studied subset of proinﬂammatory neutrophils,
termed low-density granulocytes (LDG), was identiﬁed in
the blood of SLE patients. LDGs exert cytotoxic eﬀects
on the endothelium and produce suﬃcient type I IFN to
prevent EPCs from diﬀerentiating into mature endothelial
cells. Depletion of LDGs restores the functional capacity of
the EPCs/CACs in vitro, therefore, supporting a role of these
abnormal cells and of type I IFN in the pathogenesis of
vascular damage in SLE [124].
Interestingly a recent study investigating the immuno-
modulatory eﬀects of statins in SLE demonstrated that
simvastatin and pitavastatin signiﬁcantly inhibit type I IFN
production both from pDCs isolated from lupus patients
and from healthy pDCs treated with sera from SLE patients.
The inhibitory eﬀe c to nt y p eII F Np r o d u c t i o nw a ss h o w n
to be attributable to inactivation of Rho kinases (a family
of downstream kinases of the TLR pathway) that results in
inhibition of the p38 MAPK and Akt as well as prevention of
IRF7 nuclear translocation. These ﬁndings imply that statins
exert a beneﬁcial eﬀect in the atherosclerotic process not
only due to its lipid-lowering properties but also through
inhibition of the type I IFN production. It also provides a
rationale for a potential therapeutic use of statins in IFN-
mediated autoimmune diseases such as SLE [125].
An additional pathway by which type I IFN may be
implicated in CV disease is through platelet activation. In
a recent study, Lood et al. demonstrated that, in patients
with lupus, platelets are activated and overexpress type I
IFN-regulated proteins comparing to platelets from healthy
controls. Given that the same platelet phenotype has been
observed in patients with a history of vascular disease, they
hypothesized that type I IFN-induced platelet activation
could be implicated in the development of vascular disease
in SLE [126].
Further supporting evidence for the role of type I
IFN in atherosclerosis and especially in the formation of
foam cells came from a study by Li et al. [127]. Foam
cells derive from inﬁltrating monocytes in the subintima
wheretheydiﬀerentiateintomacrophages.Uponexposureto
oxidized-LDL (ox-LDL), macrophages expressing scavenger
receptors (SR) internalize cholesteryl ester from ox-LDL
and are transformed into foam cells which represent the
primary components of the early atherosclerotic lesion. In
this study, IFNα priming induced upregulation of SR in the
macrophages and increased foam-cell formation. Further-
more,peripheralbloodmononuclearcellsfrompatientswith
SLE overexpressed SR which was positively correlated with
increased type I IFN activity.
Finally, a recent Swedish study showed that SLE patients
with the risk allele rs10181656(G) in the STAT4 gene had
a signiﬁcantly increased risk of ischemic cerebrovascular
disease (ICVD), comparable in magnitude to that of hyper-
tension. Moreover, this SNP was associated with the presence
of two or more antiphospholid antibodies (aPLs). This study
indicates that a genetic predisposition involving the type I
IFN pathway is an important and previously unrecognised
risk factor for ICVD in SLE and that aPLs may be one
underlying mechanism [128].
These data indicate that premature atherosclerosis in
SLE patients can at least partially be attributed to increased
activation of the type I IFN system. Current attempts to
block the type I IFN activity in SLE patients may provide
therapeuticapproachesthatachievesuccessfuloveralldisease
activity control and reduce the fatal vascular events that
aﬄict these patients.
6. Concluding Remarks
Over the past years, the role of type I interferon system
in generation of distinct lupus-related clinical phenotypes
arising from skin, renal, and CNS involvement has been
increasingly appreciated. Moreover, growing evidence sug-
gests the implication of type I IFN pathway in the patho-
genesis of atherosclerosis, a frequent comorbidity in these
patients, often not fully explained by the presence of co-
existing traditional CV risk factors. Careful characterization
of clinical features associated with heightened IFN levels
would further increase our insight into lupus pathogenesis
allowingthepotentialuseoftypeIinterferonasatherapeutic
target for lupus patients characterized by speciﬁc clinical
and/or serological phenotypes.
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